Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Medicine type
Approval status
AllApproved in the United States (FDA)Approved in the European Union (EMA)In Phase 3 testingIn Phase 2 testingUsed in a way not covered by an approval, or made by a compounding pharmacyDietary supplement; not FDA-approved as a medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Laboratory or animal-stage researchControlled substance; no approved US useWithdrawn from the market
Amount of information
Showing 1–3 of 3 records
Cardarine (GW501516; also written GW1516 in anti-doping documents)
Small chemical medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Abandoned cholesterol and metabolic drug, still sold as a fat burner
Ligandrol (LGD-4033; developed as VK5211)
Small chemical medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Muscle loss after hip fracture — investigational only, and development stopped
Ibutamoren (MK-677, also written MK-0677; ibutamoren mesylate)
Small chemical medicineIn Phase 2 testingDetailed recordUse listed on the medicine record
Age-related muscle loss and fracture recovery — investigational, and the programme ended